MongoDB (NASDAQ:MDB – Free Report) had its price target reduced by Oppenheimer from $400.00 to $330.00 in a research report ...
Please contact your representative at Oppenheimer & Co to request a 1-on ... of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on ...
As of March 4, 2025, the average one-year price target for Abeona Therapeutics is $16.22/share. The forecasts range from a low of $9.60 to a high of $22.05. The average price target represents an ...
PHOENIX, AZ / ACCESS Newswire / February 20, 2025 / Crexendo®, Inc. (NASDAQ:CXDO), an award-winning ... today announced that management will attend the Oppenheimer 10th Annual Emerging Growth ...
Financial industry leaders gathered at Nasdaq's Market Structure Seminar on February 11 to explore emerging trends shaping the global markets, with artificial intelligence and regulatory evolution ...
Oppenheimer & Co. Inc. raised its stake in First Trust BuyWrite Income ETF (NASDAQ:FTHI – Free Report) by 17.3% during the 4th quarter, Holdings Channel reports. The fund owned 11,818 shares of the ...
As of March 4, 2025, the average one-year price target for Abeona Therapeutics is 16.12 GBX/share. The forecasts range from a low of 9.54 GBX to a high of 21.92 GBX. The average price target ...
Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Perform to Outperform. There are 1,111 funds or institutions reporting ...
Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from Perform to Outperform. As of February 19, 2025, the average one-year ...
Fintel reports that on February 11, 2025, Oppenheimer initiated coverage of International Business Machines (BRSE:IBM) with a Outperform recommendation. There are 4,119 funds or institutions ...
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results